ContractExclusive License Agreement • June 7th, 2017 • Clementia Pharmaceuticals Inc. • Pharmaceutical preparations • New York
Confidential Information omitted and filed separately with the Securities and Exchange Commission. Five asterisks denote omissions.
COMMERCIAL SPONSORED RESEARCH AGREEMENTCommercial Sponsored Research Agreement • June 7th, 2017 • Clementia Pharmaceuticals Inc. • Pharmaceutical preparations • California
THIS AGREEMENT is entered into this 21sr day of June, 2016 (the “Effective Date”) by Sanford Burnham Prebys Medical Discovery Institute, a California not-for-profit public benefit corporation with an address at 10901 N. Torrey Pines Road, La Jolla, California 92037 (“Institute”) and Clementia Pharmaceuticals, Inc., a privately held biopharmaceutical company with an address at 4150 Sainte-Catherine St West, Suite 550, Montreal, Quebec, H3Z 2Y5, Canada (hereinafter refe1Ted to as “Sponsor”).
Confidential Information omitted and filed separately with the Securities and Exchange Commission. Five asterisks denote omissions.Exclusive License Agreement • June 7th, 2017 • Clementia Pharmaceuticals Inc. • Pharmaceutical preparations • New York
This EXCLUSIVE LICENSE AGREEMENT (this “Agreement”) is entered into as of March 29, 2017 (the “Effective Date”) by and between Galderma Research & Development SNC, a société en nom collectif organized under the laws of France having its principal address of Les Templiers, 2400 route des Colles, 06410 Biot, France (“Galderma”), and Clementia Pharmaceuticals Inc., a corporation organized under the federal laws of Canada having its principal address of 4150 Saint-Catherine West, Suite 550, Montreal, Canada H3Z 2Y5 (“Clementia”). Each of Galderma and Clementia is sometimes referred to individually herein as a “Party” and collectively the “Parties”.
AGREEMENT FOR FEE-PER-SERVICEPer-Service • June 7th, 2017 • Clementia Pharmaceuticals Inc. • Pharmaceutical preparations
This Agreement for fee-per-service (this “Agreement’) is effective by and between Clementia Pharmaceuticals, Inc., a privately held biopharmaceutical company with an address at 4150 Sainte-Catherine St. West, Suite 550, Montreal, Quebec, H3Z 2Y5, in the person of Clarissa Desjardins, PhD, CEO (“Clementia”), and Istituto Ortopedico Rizzoli, a public institution with registered office in Bologna, Via di Barbiano n. 1/10 (CAP. 40136), Tax ID and VAT n. 00302030374, in the person of the Chief of SC Amministrazione della Ricerca, Dr. Pierpaola D’Alessandro, [*****], authorized to the signature of this Agreement on behalf of Legal Representative, by IOR Resolution nr. 199 of 2016, Aug 1st (“Rizzoli”/“IOR”) hereafter referred as “Party”/“Parties”.
Palovarotene Program Consultancy AGREEMENT between Clementia Pharmaceuticals Inc., 4150 Ste-Catherine St West, suite 550, Montreal Quebec H3Z 2Y5 Canada and Luca Sangiorgi, MD PhD Vicolo Malgrado 9, 40125 Bologna ItalyPalovarotene Program Consultancy Agreement • June 7th, 2017 • Clementia Pharmaceuticals Inc. • Pharmaceutical preparations • Massachusetts
